Celgene, Barr Resolve Spat Over Generic Thalomid
Pharmaceutical company Celgene Corp. and generic-drug maker Barr Laboratories Inc. have resolved their dispute over generic competition for the cancer drug Thalomid, with Celgene agreeing to drop its patent infringement claims...To view the full article, register now.
Already a subscriber? Click here to view full article